Attached files
| file | filename |
|---|---|
| EX-99.1 - MATERIALS TO BE PRESENTED APRIL 4, 2012 - K-V Pharmaceutical Co | d329143dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 4, 2011
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
| Delaware | 1-9601 | 43-0618919 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 2280 Schuetz Road St. Louis, MO |
63146 | |||
| (Address of principal executive offices) | (Zip Code) | |||
(314) 645-6600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
| Item 8.01 | Other Events. |
On April 2, 2012, K-V Pharmaceutical Company (the “Company”) issued a press release announcing that Thomas McHugh, Chief Financial Officer of the Company, is scheduled to present at the Needham & Company 11th Annual Healthcare Conference on Wednesday, April 4, 2012 at 2:00 p.m. EDT. Attached is a copy of the materials to be presented.
| Item 9.01 | Financial Statements and Exhibits. |
The following information is filed as part of this report:
| Exhibit |
Description | |
| 99.1 | Materials to be presented at the April 4, 2012 Needham & Company 11th Annual Healthcare Conference. | |
The Registrant will post this Form 8-K on its Internet website at www.kvpharmaceutical.com. References to the Registrant’s website address are included in this Form 8-K only as inactive textual references and the Registrant does not intend them to be active links to its website. Information contained on the Registrant’s website does not constitute part of this Form 8-K.
* * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| K-V PHARMACEUTICAL COMPANY | ||||||
| Dated: April 4, 2012 | By: | /s/ Patrick J. Christmas | ||||
| Patrick J. Christmas | ||||||
| VP, General Counsel and Secretary | ||||||